Oppenheimer Believes Spero Therapeutics (NASDAQ: SPRO) Won’t Stop Here

By Ryan Adsit

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Spero Therapeutics (SPROResearch Report) today and set a price target of $19.00. The company’s shares closed last Friday at $14.02, close to its 52-week high of $14.60.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 26.1% and a 51.8% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

Currently, the analyst consensus on Spero Therapeutics is a Strong Buy with an average price target of $24.00.

See today’s analyst top recommended stocks >>

Based on Spero Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.73 million and GAAP net loss of $17.5 million. In comparison, last year the company earned revenue of $2.16 million and had a GAAP net loss of $13.15 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.